Advertisement

Topics

EMA Validates Marketing Authorization for Ipsen Carcinoma Treatment

05:12 EDT 11 Sep 2017 | PharmPro

Ipsen receives validation from European Medicines Agency for the application of a new indication for Cabometyx (cabozantinib) for first-line treatment of advanced renal cell carcinoma in adults.
Contributed Author: 
Ipsen

Original Article: EMA Validates Marketing Authorization for Ipsen Carcinoma Treatment

NEXT ARTICLE

More From BioPortfolio on "EMA Validates Marketing Authorization for Ipsen Carcinoma Treatment"

Quick Search
Advertisement
 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...